tetano
Editor, Senior Moderator
Allergy Asthma Proc
. 2022 Jan 1;43(1):37-39.
doi: 10.2500/aap.2022.43.210100.
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose
Megan C Gallagher[SUP] 1 [/SUP], Sarah Haessler[SUP] 1 [/SUP], Elizabeth Pecoy-Whitcomb[SUP] 2 [/SUP], Jonathan Bayuk[SUP] 3 [/SUP]
Affiliations
Abstract
Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available.
. 2022 Jan 1;43(1):37-39.
doi: 10.2500/aap.2022.43.210100.
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose
Megan C Gallagher[SUP] 1 [/SUP], Sarah Haessler[SUP] 1 [/SUP], Elizabeth Pecoy-Whitcomb[SUP] 2 [/SUP], Jonathan Bayuk[SUP] 3 [/SUP]
Affiliations
- PMID: 34983708
- DOI: 10.2500/aap.2022.43.210100
Abstract
Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available.